European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the agency recommended for approval in November for some patients with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback